AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

CVE:PASPascal Biosciences Stock Price, Forecast & News

C$0.13
+0.01 (+8.33 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
C$0.13
Now: C$0.13
C$0.13
50-Day Range
C$0.07
MA: C$0.10
C$0.12
52-Week Range
C$0.07
Now: C$0.13
C$0.20
Volume631 shs
Average Volume77,358 shs
Market CapitalizationC$7.34 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pascal Biosciences Inc., a drug discovery and development company, researches and develops biotechnology products for the treatment of cancer and for the enhancement of immune system in Canada. Its research programs include the development of Anti-VpreB, a therapeutic monoclonal antibody for treatment of B-cell precursor acute lymphoblastic leukemia in collaboration with the University of New Mexico; optimization of novel classes of molecules that restore immune recognition and killing of cancer cells; and regulating activity of immune system calcium channels to combat cancers, infections, and autoimmune diseases. The company has a collaboration agreement with the University of British Columbia. Pascal Biosciences Inc. is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-6886775

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.01 per share
Book ValueC$0.00 per share

Profitability

Miscellaneous

Employees4
Market CapC$7.34 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PAS News and Ratings via Email

Sign-up to receive the latest news and ratings for PAS and its competitors with MarketBeat's FREE daily newsletter.

Pascal Biosciences (CVE:PAS) Frequently Asked Questions

How has Pascal Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Pascal Biosciences' stock was trading at C$0.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PAS stock has increased by 30.0% and is now trading at C$0.13. View which stocks have been most impacted by Coronavirus.

Has Pascal Biosciences been receiving favorable news coverage?

News coverage about PAS stock has been trending positive this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pascal Biosciences earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the stock's share price in the immediate future. View the latest news aboutPascal Biosciences.

Who are some of Pascal Biosciences' key competitors?

What other stocks do shareholders of Pascal Biosciences own?

Who are Pascal Biosciences' key executives?

Pascal Biosciences' management team includes the following people:
  • Dr. Patrick W. Gray, CEO & Director (Age 67)
  • Ms. Judith F. Dalling L.L.B., CFO & Corp. Sec. (Age 64)
  • Mr. Carl Weissman, Acting Pres (Age 57)

What is Pascal Biosciences' stock symbol?

Pascal Biosciences trades on the Canadian Venture Exchange (CVE) under the ticker symbol "PAS."

How do I buy shares of Pascal Biosciences?

Shares of PAS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Pascal Biosciences' stock price today?

One share of PAS stock can currently be purchased for approximately C$0.13.

How big of a company is Pascal Biosciences?

Pascal Biosciences has a market capitalization of C$7.34 million. Pascal Biosciences employs 4 workers across the globe.

What is Pascal Biosciences' official website?

The official website for Pascal Biosciences is www.biommune.net.

How can I contact Pascal Biosciences?

Pascal Biosciences' mailing address is 400 Burrard St Suite 1780, VANCOUVER, BC V6C 3A6, Canada. The company can be reached via phone at +1-604-6886775.

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.